<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100058</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066B2201</org_study_id>
    <secondary_id>2016-002868-14</secondary_id>
    <nct_id>NCT03100058</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults</brief_title>
  <official_title>A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a dose-finding study that evaluated the change in weight after 24 weeks treatment
      with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed
      by 24 weeks treatment with 2 doses of LIK066 and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2017</start_date>
  <completion_date type="Actual">August 2, 2018</completion_date>
  <primary_completion_date type="Actual">March 2, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Body Weight at 24 Weeks</measure>
    <time_frame>Baseline, Week 24 (Epoch 3)</time_frame>
    <description>Dose-response relationship of two dose regimens of LIK066 as measured by the percent change from baseline in body weight relative to placebo after 24 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Response Rate According to Percent Decrease in Body Weight for Overall Study</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Responder rates according to percentage decrease in body weight either ≥ 5 % or ≥ 10 % from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Response Rate According to Percent Decrease in Body Weight for Subgroups</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Responder rates according to percentage decrease in body weight either ≥ 5 % or ≥ 10 % from baseline for dysglycemic, normoglycemic, Type 2 Diabetes Mellitus (T2DM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline on Waist Circumference</measure>
    <time_frame>Baseline, Week 24 (Epoch 3), Week 24 to Week 48 (Epoch 4)</time_frame>
    <description>Waist circumference will be measured to the nearest 0.1cm in a standing position, at the end of a normal expiration, using a tape at the level of the iliac crest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) in Type 2 Diabetes Mellitus Patients (T2DM)</measure>
    <time_frame>Baseline, Week 24 (Epoch 3), Week 24 to Week 48 (Epoch 4)</time_frame>
    <description>FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycated Hemoglobin A1c (HbA1c) in Type 2 Diabetes Mellitus Patients (T2DM)</measure>
    <time_frame>Baseline, Week 24 (Epoch 3), Week 24 to week 48 (Epoch 4)</time_frame>
    <description>HbA1c will be measured from a blood sample obtained at indicated visits and will be analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>Baseline, Week 24 (Epoch 3) Week 24 to Week 48 (Epoch 4)</time_frame>
    <description>At each study visit (baseline, week 24, Week 48), after the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP and DBP will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24-hour Urinary Glucose Excretion</measure>
    <time_frame>Baseline, week 24 (Epoch 3), Week 24 to Week 48 (Epoch 4)</time_frame>
    <description>Urinary glucose excretion will be measured from 24-hour urinary collection at indicated visits and will be analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Weight in the Overall Population and by Subgroups (Epoch 4)</measure>
    <time_frame>Between Week 24 and Week 48 (Epoch 4)</time_frame>
    <description>Between -treatment analysis of percentage change from Week 24 in body weight (kg) at Week 48 (Epoch 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 (Epoch 3) in the 24-hour Urinary Calcium Excretion</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Evaluation of 24-hour urinary calcium excretion after 24 week of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Week 24 to Week 48 (Epoch 4) in the 24-hour Urinary Calcium Excretion</measure>
    <time_frame>Baseline, Week 24, Week 48</time_frame>
    <description>Evaluation of 24-hour urinary calcium after 48 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 (Epoch 3) in the 24-hour Urinary Phosphorus Excretion</measure>
    <time_frame>Week 24, Week 48</time_frame>
    <description>Evaluation of 24-hour urinary phosphorus excretion after 24 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Week 24 to Week 48 (Epoch 4) in the 24-hour Urinary Phosphorus Excretion</measure>
    <time_frame>Week 24, Week 48</time_frame>
    <description>Evaluation of 24-hour urinary phosphorus excretion after 48 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Lipid Profile (Lipoproteins)</measure>
    <time_frame>Baseline, Week 24, Week 24 to Week 48 (Epoch 4)</time_frame>
    <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitive C-reactive Protein (hsCRP)</measure>
    <time_frame>Baseline to Week 24, Week 24 to Week 48 (Epoch 4)</time_frame>
    <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Lipid Profile (Triglycerides/Cholesterol)</measure>
    <time_frame>Baseline to Week 24, Week 24 to Week 48 (Epoch 4)</time_frame>
    <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Observe Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Summary at Week 24 from qd or bid regimens</time_frame>
    <description>Observe maximum plasma concentration following administration of LIK066 (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Time to Reach the Maximum Concentration (Tmax)</measure>
    <time_frame>Summary at Week 24 for qd or bid regimens</time_frame>
    <description>Time to reach the maximum concentration after administration of LIK066 (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Area Under the Plasma Concentration-time Curve From Time Zero Time 't' (AUC0-t)</measure>
    <time_frame>Summary at Week 24 from qd or bid regimens (0-6h)</time_frame>
    <description>Area under the plasma concentration-time curve from time zero time 't' where t is a defined time point after administration (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Last Non-zero Concentration Area Under the Curve (AUClast)</measure>
    <time_frame>Summary at Week 24 from qd or bid regimens</time_frame>
    <description>Last non-zero concentration area under the curve (AUClast)</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>LIK066 2.5mg qd (Epoch 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Epoch 3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 10mg qd (Epoch 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 50mg qd (Epoch 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 150mg qd (Epoch 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 2.5mg bid (Epoch 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 5mg bid (Epoch 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 5mg bid (once daily) dosing frequency for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 25mg bid (Epoch 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 25mg bid (once daily) dosing frequency for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 50mg bid (Epoch 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LIK066 50mg bid dosing frequency for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 qd/LIK066 25mg qd (Epoch 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIK066 bid/LIK066 35mg qd (Epoch 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/LIK066 25mg qd (Epoch 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Placebo (Epoch 4)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>LIK066 will be supplied in different doses as tablets to be taken orally.</description>
    <arm_group_label>LIK066 10mg qd (Epoch 3)</arm_group_label>
    <arm_group_label>LIK066 150mg qd (Epoch 3)</arm_group_label>
    <arm_group_label>LIK066 2.5mg bid (Epoch 3)</arm_group_label>
    <arm_group_label>LIK066 2.5mg qd (Epoch 3)</arm_group_label>
    <arm_group_label>LIK066 25mg bid (Epoch 3)</arm_group_label>
    <arm_group_label>LIK066 50mg bid (Epoch 3)</arm_group_label>
    <arm_group_label>LIK066 50mg qd (Epoch 3)</arm_group_label>
    <arm_group_label>LIK066 5mg bid (Epoch 3)</arm_group_label>
    <arm_group_label>LIK066 bid/LIK066 35mg qd (Epoch 4)</arm_group_label>
    <arm_group_label>LIK066 qd/LIK066 25mg qd (Epoch 4)</arm_group_label>
    <arm_group_label>Placebo/LIK066 25mg qd (Epoch 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo (Epoch 3)</arm_group_label>
    <arm_group_label>Placebo/Placebo (Epoch 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. informed consent

          2. (BMI&gt;=30) or (BMI&gt;=27 with history of CV disease, hypertension, dyslipidemia,
             pre-diabetes or type 2 diabetes mellitus, sleep-apnea syndrome)

          3. willing to comply with life-style intervention and treatment during the full duration
             of the study (approximately 54 weeks)

        Exclusion Criteria:

          -  Hypersensitivity to any of the study medications

          -  Pregnancy or lactating women

          -  History of malignancies

          -  Use of pharmacologically active weight loss products

          -  Bariatric surgery

          -  Ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening
             visit.

          -  HbA1c &gt;10% at the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wauconda</city>
        <state>Illinois</state>
        <zip>60084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <zip>70403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beltsville</city>
        <state>Maryland</state>
        <zip>20705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6W 5M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <state>Czech Republic</state>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc Lazce</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 1</city>
        <zip>116 94</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 3</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Slany</city>
        <zip>274 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Csongrad</city>
        <zip>6640</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>85101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sered</city>
        <zip>92601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basingstoke</city>
        <zip>RG24 9DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blackburn</city>
        <zip>BB2 1AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotherham</city>
        <zip>S65 1DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stevenage</city>
        <zip>SG1 4AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Slovakia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <results_first_submitted>July 30, 2019</results_first_submitted>
  <results_first_submitted_qc>January 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 6, 2020</results_first_posted>
  <disposition_first_submitted>January 16, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 16, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 17, 2019</disposition_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Overweight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03100058/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03100058/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall, 674 patients were screened. Of the 460 patients who were randomized to the study, the majority (85.7%) completed Epoch 3. Of the 394 patients who completed Epoch 3 and entered Epoch 4, the majority (93.1%) completed the Epoch 4 study period.</recruitment_details>
      <pre_assignment_details>Overall, 674 patients were screened. Of the 460 patients who were randomized to the study, the majority (85.7%) completed Epoch 3. Of the 394 patients who completed Epoch 3 and entered Epoch 4, the majority (93.1%) completed the Epoch 4 study period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LIK066 2.5mg qd (Epoch 3)</title>
          <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>LIK066 10mg qd (Epoch 3)</title>
          <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>LIK066 50mg qd (Epoch 3)</title>
          <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="P4">
          <title>LIK066 150mg qd (Epoch 3)</title>
          <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="P5">
          <title>LIK066 2.5mg Bid (Epoch 3)</title>
          <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="P6">
          <title>LIK066 5mg Bid (Epoch 3)</title>
          <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="P7">
          <title>LIK066 25mg Bid (Epoch 3)</title>
          <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="P8">
          <title>LIK066 50mg Bid (Epoch 3)</title>
          <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="P9">
          <title>Placebo (Epoch 3)</title>
          <description>Matching placebo tablets for 24 weeks</description>
        </group>
        <group group_id="P10">
          <title>LIK066 qd/LIK066 25 mg qd (Epoch 4)</title>
          <description>LIK066 qd (once daily) patients who entered Epoch 4 and received LIK066 25 mg qd</description>
        </group>
        <group group_id="P11">
          <title>LIK066 Bid/LIK066 35 mg qd (Epoch 4)</title>
          <description>LIK066 bid patients who entered Epoch 4 and received LIK066 35 mg qd</description>
        </group>
        <group group_id="P12">
          <title>Placebo/LIK066 25 mg qd (Epoch 4)</title>
          <description>Matching placebo tablets for 24 weeks</description>
        </group>
        <group group_id="P13">
          <title>Placebo qd (Epoch 4)</title>
          <description>Placebo patients who entered Epoch 4 and received matching Placebo tablets qd</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Epoch 3 (24 Weeks of Treatment)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="77"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="38"/>
                <participants group_id="P8" count="76"/>
                <participants group_id="P9" count="78"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="60"/>
                <participants group_id="P9" count="73"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="16"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Epoch 4 (Last 24 Weeks of the Study)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="158"/>
                <participants group_id="P11" count="163"/>
                <participants group_id="P12" count="39"/>
                <participants group_id="P13" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="153"/>
                <participants group_id="P11" count="148"/>
                <participants group_id="P12" count="36"/>
                <participants group_id="P13" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="15"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LIK066 2.5mg qd (Epoch 3)</title>
          <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>LIK066 10mg qd (Epoch 3)</title>
          <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>LIK066 50mg qd (Epoch 3)</title>
          <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="B4">
          <title>LIK066 150mg qd (Epoch 3)</title>
          <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="B5">
          <title>LIK066 2.5mg Bid (Epoch 3)</title>
          <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="B6">
          <title>LIK066 5mg Bid (Epoch 3)</title>
          <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="B7">
          <title>LIK066 25mg Bid (Epoch 3)</title>
          <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="B8">
          <title>LIK066 50mg Bid (Epoch 3)</title>
          <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="B9">
          <title>Placebo (Epoch 3)</title>
          <description>Matching placebo tablets for 24 weeks</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="77"/>
            <count group_id="B5" value="38"/>
            <count group_id="B6" value="39"/>
            <count group_id="B7" value="38"/>
            <count group_id="B8" value="76"/>
            <count group_id="B9" value="78"/>
            <count group_id="B10" value="460"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="12.20"/>
                    <measurement group_id="B2" value="53.2" spread="10.08"/>
                    <measurement group_id="B3" value="52.9" spread="13.60"/>
                    <measurement group_id="B4" value="51.1" spread="12.94"/>
                    <measurement group_id="B5" value="53.4" spread="12.28"/>
                    <measurement group_id="B6" value="49.8" spread="11.50"/>
                    <measurement group_id="B7" value="49.7" spread="11.93"/>
                    <measurement group_id="B8" value="52.9" spread="11.87"/>
                    <measurement group_id="B9" value="51.1" spread="13.27"/>
                    <measurement group_id="B10" value="51.7" spread="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="49"/>
                    <measurement group_id="B9" value="45"/>
                    <measurement group_id="B10" value="283"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="33"/>
                    <measurement group_id="B10" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="63"/>
                    <measurement group_id="B9" value="64"/>
                    <measurement group_id="B10" value="392"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Body Weight at 24 Weeks</title>
        <description>Dose-response relationship of two dose regimens of LIK066 as measured by the percent change from baseline in body weight relative to placebo after 24 weeks of treatment</description>
        <time_frame>Baseline, Week 24 (Epoch 3)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Body Weight at 24 Weeks</title>
          <description>Dose-response relationship of two dose regimens of LIK066 as measured by the percent change from baseline in body weight relative to placebo after 24 weeks of treatment</description>
          <population>Full Analysis Set</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" lower_limit="-2.50" upper_limit="-0.45"/>
                    <measurement group_id="O2" value="-2.04" lower_limit="-3.36" upper_limit="-0.88"/>
                    <measurement group_id="O3" value="-3.52" lower_limit="-4.62" upper_limit="-1.87"/>
                    <measurement group_id="O4" value="-4.37" lower_limit="-5.36" upper_limit="-3.37"/>
                    <measurement group_id="O5" value="-1.67" lower_limit="-2.61" upper_limit="-0.27"/>
                    <measurement group_id="O6" value="-2.51" lower_limit="-3.94" upper_limit="-1.32"/>
                    <measurement group_id="O7" value="-4.06" lower_limit="-5.52" upper_limit="-2.87"/>
                    <measurement group_id="O8" value="-4.47" lower_limit="-5.49" upper_limit="-3.48"/>
                    <measurement group_id="O9" value="-0.63" lower_limit="-1.56" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.17</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.36</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.86</ci_lower_limit>
            <ci_upper_limit>-1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.39</ci_lower_limit>
            <ci_upper_limit>-3.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.11</ci_lower_limit>
            <ci_upper_limit>-1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.54</ci_lower_limit>
            <ci_upper_limit>-2.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.54</ci_lower_limit>
            <ci_upper_limit>-3.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Response Rate According to Percent Decrease in Body Weight for Overall Study</title>
        <description>Responder rates according to percentage decrease in body weight either ≥ 5 % or ≥ 10 % from baseline</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Response Rate According to Percent Decrease in Body Weight for Overall Study</title>
          <description>Responder rates according to percentage decrease in body weight either ≥ 5 % or ≥ 10 % from baseline</description>
          <population>Full Analysis Set</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="75"/>
                <count group_id="O9" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="34.2"/>
                    <measurement group_id="O4" value="42.9"/>
                    <measurement group_id="O5" value="15.8"/>
                    <measurement group_id="O6" value="20.5"/>
                    <measurement group_id="O7" value="37.8"/>
                    <measurement group_id="O8" value="45.3"/>
                    <measurement group_id="O9" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="5.3"/>
                    <measurement group_id="O4" value="6.5"/>
                    <measurement group_id="O5" value="5.3"/>
                    <measurement group_id="O6" value="2.6"/>
                    <measurement group_id="O7" value="10.8"/>
                    <measurement group_id="O8" value="9.3"/>
                    <measurement group_id="O9" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.099</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>6.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.779</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>3.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>10.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;.001</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.41</ci_lower_limit>
            <ci_upper_limit>12.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.812</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>3.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.229</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>5.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>11.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;.001</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.72</ci_lower_limit>
            <ci_upper_limit>14.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=10%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.943</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>12.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=10%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.465</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>15.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=10%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.696</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>17.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=10%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.389</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>12.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=10%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.976</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>11.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=10%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.986</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>11.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=10%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.181</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>22.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=10%</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.100</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>20.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Response Rate According to Percent Decrease in Body Weight for Subgroups</title>
        <description>Responder rates according to percentage decrease in body weight either ≥ 5 % or ≥ 10 % from baseline for dysglycemic, normoglycemic, Type 2 Diabetes Mellitus (T2DM)</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Response Rate According to Percent Decrease in Body Weight for Subgroups</title>
          <description>Responder rates according to percentage decrease in body weight either ≥ 5 % or ≥ 10 % from baseline for dysglycemic, normoglycemic, Type 2 Diabetes Mellitus (T2DM)</description>
          <population>Full Analysis Set</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="75"/>
                <count group_id="O9" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dysglycemic (&gt;=5%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="48.4"/>
                    <measurement group_id="O5" value="6.7"/>
                    <measurement group_id="O6" value="37.5"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="41.9"/>
                    <measurement group_id="O9" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normoglycemic (&gt;=5%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="47.4"/>
                    <measurement group_id="O5" value="11.1"/>
                    <measurement group_id="O6" value="11.1"/>
                    <measurement group_id="O7" value="55.6"/>
                    <measurement group_id="O8" value="52.9"/>
                    <measurement group_id="O9" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type 2 Diabetes Mellitus (T2DM) (&gt;=5%)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="27"/>
                    <count group_id="O9" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="37.0"/>
                    <measurement group_id="O5" value="28.6"/>
                    <measurement group_id="O6" value="14.3"/>
                    <measurement group_id="O7" value="30.8"/>
                    <measurement group_id="O8" value="44.4"/>
                    <measurement group_id="O9" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Dysglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.048</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>38.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Dsyglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.171</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>3.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>28.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Dysglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.041</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>47.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Dysglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.32</ci_lower_limit>
            <ci_upper_limit>60.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Dysglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.976</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.08</ci_lower_limit>
            <ci_upper_limit>11.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Dysglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.37</ci_lower_limit>
            <ci_upper_limit>56.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Dysglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.032</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>46.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Dysglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>11.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.11</ci_lower_limit>
            <ci_upper_limit>60.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Normoglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.227</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>21.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Normoglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.763</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>7.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Normoglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.095</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>28.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Normoglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.033</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>24.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Normoglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.788</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>8.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Normoglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.751</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>7.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Normoglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.027</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>51.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (Normoglycemic)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.023</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>34.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (T2DM)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.528</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>4.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (T2DM)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.958</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (T2DM)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.546</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>9.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (T2DM)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding test</non_inferiority_desc>
            <p_value>0.098</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>11.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (T2DM)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.563</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>8.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (T2DM)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.610</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>5.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (T2DM)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.528</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>9.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>&gt;=5% (T2DM)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.023</p_value>
            <method>ANCOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>16.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline on Waist Circumference</title>
        <description>Waist circumference will be measured to the nearest 0.1cm in a standing position, at the end of a normal expiration, using a tape at the level of the iliac crest.</description>
        <time_frame>Baseline, Week 24 (Epoch 3), Week 24 to Week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
          <group group_id="O10">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O11">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O12">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O13">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline on Waist Circumference</title>
          <description>Waist circumference will be measured to the nearest 0.1cm in a standing position, at the end of a normal expiration, using a tape at the level of the iliac crest.</description>
          <population>Full Analysis Set</population>
          <units>Percentage Change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="158"/>
                <count group_id="O11" value="163"/>
                <count group_id="O12" value="39"/>
                <count group_id="O13" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-3.87" upper_limit="-0.31"/>
                    <measurement group_id="O2" value="-2.7" lower_limit="-4.55" upper_limit="-0.92"/>
                    <measurement group_id="O3" value="-3.7" lower_limit="-5.55" upper_limit="-1.82"/>
                    <measurement group_id="O4" value="-5.6" lower_limit="-6.84" upper_limit="-4.35"/>
                    <measurement group_id="O5" value="-2.7" lower_limit="-4.47" upper_limit="-0.91"/>
                    <measurement group_id="O6" value="-4.3" lower_limit="-6.07" upper_limit="-2.57"/>
                    <measurement group_id="O7" value="-4.8" lower_limit="-6.61" upper_limit="-2.98"/>
                    <measurement group_id="O8" value="-4.6" lower_limit="-5.89" upper_limit="-3.31"/>
                    <measurement group_id="O9" value="-1.3" lower_limit="-2.54" upper_limit="-0.05"/>
                    <measurement group_id="O10" value="-0.4" lower_limit="-1.25" upper_limit="0.36"/>
                    <measurement group_id="O11" value="-0.7" lower_limit="-1.53" upper_limit="0.10"/>
                    <measurement group_id="O12" value="-2.1" lower_limit="-3.73" upper_limit="-0.38"/>
                    <measurement group_id="O13" value="0.4" lower_limit="-1.37" upper_limit="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.470</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.96</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.199</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.64</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.206</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.56</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.18</ci_lower_limit>
            <ci_upper_limit>-0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.70</ci_lower_limit>
            <ci_upper_limit>-1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.10</ci_lower_limit>
            <ci_upper_limit>-1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.391</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.82</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.259</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.10</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.048</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.91</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) in Type 2 Diabetes Mellitus Patients (T2DM)</title>
        <description>FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake).</description>
        <time_frame>Baseline, Week 24 (Epoch 3), Week 24 to Week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
          <group group_id="O10">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O11">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O12">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O13">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) in Type 2 Diabetes Mellitus Patients (T2DM)</title>
          <description>FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake).</description>
          <population>Full Analysis Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="158"/>
                <count group_id="O11" value="163"/>
                <count group_id="O12" value="39"/>
                <count group_id="O13" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.55" upper_limit="3.19"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-1.46" upper_limit="1.27"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-2.60" upper_limit="0.26"/>
                    <measurement group_id="O4" value="-0.8" lower_limit="-1.70" upper_limit="0.16"/>
                    <measurement group_id="O5" value="-0.5" lower_limit="-1.80" upper_limit="0.86"/>
                    <measurement group_id="O6" value="-1.1" lower_limit="-2.37" upper_limit="0.27"/>
                    <measurement group_id="O7" value="-0.9" lower_limit="-2.28" upper_limit="0.46"/>
                    <measurement group_id="O8" value="-1.0" lower_limit="-1.96" upper_limit="-0.13"/>
                    <measurement group_id="O9" value="0.9" lower_limit="-0.06" upper_limit="1.81"/>
                    <measurement group_id="O10" value="-0.1" lower_limit="-0.64" upper_limit="0.35"/>
                    <measurement group_id="O11" value="-0.3" lower_limit="-0.79" upper_limit="0.22"/>
                    <measurement group_id="O12" value="-0.1" lower_limit="-1.14" upper_limit="0.84"/>
                    <measurement group_id="O13" value="0.6" lower_limit="-0.54" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.225</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.247</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.62</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.75</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.96</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.106</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.97</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.54</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.035</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.44</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.22</ci_lower_limit>
            <ci_upper_limit>-0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycated Hemoglobin A1c (HbA1c) in Type 2 Diabetes Mellitus Patients (T2DM)</title>
        <description>HbA1c will be measured from a blood sample obtained at indicated visits and will be analyzed at a central laboratory.</description>
        <time_frame>Baseline, Week 24 (Epoch 3), Week 24 to week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
          <group group_id="O10">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O11">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O12">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O13">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycated Hemoglobin A1c (HbA1c) in Type 2 Diabetes Mellitus Patients (T2DM)</title>
          <description>HbA1c will be measured from a blood sample obtained at indicated visits and will be analyzed at a central laboratory.</description>
          <population>Full Analysis Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="158"/>
                <count group_id="O11" value="163"/>
                <count group_id="O12" value="39"/>
                <count group_id="O13" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.23" upper_limit="0.45"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-0.82" upper_limit="-0.13"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-1.24" upper_limit="-0.50"/>
                    <measurement group_id="O4" value="-0.7" lower_limit="-0.92" upper_limit="-0.44"/>
                    <measurement group_id="O5" value="-0.3" lower_limit="-0.68" upper_limit="0.00"/>
                    <measurement group_id="O6" value="-0.5" lower_limit="-0.83" upper_limit="-0.15"/>
                    <measurement group_id="O7" value="-0.6" lower_limit="-0.98" upper_limit="-0.28"/>
                    <measurement group_id="O8" value="-0.6" lower_limit="-0.87" upper_limit="-0.40"/>
                    <measurement group_id="O9" value="-0.3" lower_limit="-0.50" upper_limit="-0.02"/>
                    <measurement group_id="O10" value="0.2" lower_limit="0.03" upper_limit="0.38"/>
                    <measurement group_id="O11" value="0.0" lower_limit="-0.13" upper_limit="0.22"/>
                    <measurement group_id="O12" value="-0.1" lower_limit="-0.49" upper_limit="0.24"/>
                    <measurement group_id="O13" value="0.3" lower_limit="-0.07" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.082</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.319</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.707</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.280</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.086</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.030</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>At each study visit (baseline, week 24, Week 48), after the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP and DBP will be measured</description>
        <time_frame>Baseline, Week 24 (Epoch 3) Week 24 to Week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
          <group group_id="O10">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O11">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O12">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O13">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>At each study visit (baseline, week 24, Week 48), after the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP and DBP will be measured</description>
          <population>Full Analysis Set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="158"/>
                <count group_id="O11" value="163"/>
                <count group_id="O12" value="39"/>
                <count group_id="O13" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>systolic blood pressure (SBP)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="37"/>
                    <count group_id="O8" value="75"/>
                    <count group_id="O9" value="78"/>
                    <count group_id="O10" value="58"/>
                    <count group_id="O11" value="162"/>
                    <count group_id="O12" value="37"/>
                    <count group_id="O13" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-4.38" upper_limit="1.93"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-4.38" upper_limit="1.93"/>
                    <measurement group_id="O3" value="-4.9" lower_limit="-8.30" upper_limit="-1.52"/>
                    <measurement group_id="O4" value="-1.2" lower_limit="-3.38" upper_limit="1.06"/>
                    <measurement group_id="O5" value="-0.7" lower_limit="-3.86" upper_limit="2.43"/>
                    <measurement group_id="O6" value="0.8" lower_limit="-2.38" upper_limit="3.88"/>
                    <measurement group_id="O7" value="-2.6" lower_limit="-5.82" upper_limit="0.69"/>
                    <measurement group_id="O8" value="-1.8" lower_limit="-4.15" upper_limit="0.48"/>
                    <measurement group_id="O9" value="1.6" lower_limit="-0.67" upper_limit="3.80"/>
                    <measurement group_id="O10" value="-0.9" lower_limit="-2.66" upper_limit="0.79"/>
                    <measurement group_id="O11" value="-1.6" lower_limit="-3.39" upper_limit="0.10"/>
                    <measurement group_id="O12" value="-5.6" lower_limit="-9.22" upper_limit="-2.06"/>
                    <measurement group_id="O13" value="0.8" lower_limit="-2.97" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic blood pressure (DBP)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="37"/>
                    <count group_id="O8" value="75"/>
                    <count group_id="O9" value="78"/>
                    <count group_id="O10" value="158"/>
                    <count group_id="O11" value="162"/>
                    <count group_id="O12" value="37"/>
                    <count group_id="O13" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-2.37" upper_limit="2.00"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-2.21" upper_limit="2.40"/>
                    <measurement group_id="O3" value="-2.3" lower_limit="-4.62" upper_limit="0.07"/>
                    <measurement group_id="O4" value="-1.3" lower_limit="-2.82" upper_limit="0.26"/>
                    <measurement group_id="O5" value="0.8" lower_limit="-1.35" upper_limit="3.02"/>
                    <measurement group_id="O6" value="-1.4" lower_limit="-3.57" upper_limit="0.78"/>
                    <measurement group_id="O7" value="0.3" lower_limit="-1.99" upper_limit="2.54"/>
                    <measurement group_id="O8" value="-1.7" lower_limit="-3.26" upper_limit="-0.06"/>
                    <measurement group_id="O9" value="0.5" lower_limit="-1.03" upper_limit="2.08"/>
                    <measurement group_id="O10" value="-0.6" lower_limit="-1.69" upper_limit="0.56"/>
                    <measurement group_id="O11" value="-1.2" lower_limit="-2.30" upper_limit="-0.04"/>
                    <measurement group_id="O12" value="-2.0" lower_limit="-4.33" upper_limit="0.34"/>
                    <measurement group_id="O13" value="0.6" lower_limit="-1.89" upper_limit="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.156</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.64</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.127</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.11</ci_lower_limit>
            <ci_upper_limit>0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.52</ci_lower_limit>
            <ci_upper_limit>-2.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.089</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.86</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.245</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.12</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.678</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.65</ci_lower_limit>
            <ci_upper_limit>3.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.040</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.07</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>SBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.038</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.61</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.601</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.38</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.760</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.20</ci_lower_limit>
            <ci_upper_limit>2.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.051</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.60</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.105</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.98</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.820</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.36</ci_lower_limit>
            <ci_upper_limit>2.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.157</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.58</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.859</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.99</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>DBP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.054</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.41</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24-hour Urinary Glucose Excretion</title>
        <description>Urinary glucose excretion will be measured from 24-hour urinary collection at indicated visits and will be analyzed at a central laboratory.</description>
        <time_frame>Baseline, week 24 (Epoch 3), Week 24 to Week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
          <group group_id="O10">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O11">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O12">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O13">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24-hour Urinary Glucose Excretion</title>
          <description>Urinary glucose excretion will be measured from 24-hour urinary collection at indicated visits and will be analyzed at a central laboratory.</description>
          <population>Full Analysis Set</population>
          <units>mmol/24hr</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="158"/>
                <count group_id="O11" value="163"/>
                <count group_id="O12" value="39"/>
                <count group_id="O13" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.6" lower_limit="101.85" upper_limit="315.40"/>
                    <measurement group_id="O2" value="134.6" lower_limit="-8.69" upper_limit="277.85"/>
                    <measurement group_id="O3" value="377.0" lower_limit="206.19" upper_limit="547.90"/>
                    <measurement group_id="O4" value="306.1" lower_limit="199.59" upper_limit="412.62"/>
                    <measurement group_id="O5" value="183.0" lower_limit="32.37" upper_limit="333.70"/>
                    <measurement group_id="O6" value="193.8" lower_limit="82.22" upper_limit="305.31"/>
                    <measurement group_id="O7" value="241.3" lower_limit="135.13" upper_limit="347.30"/>
                    <measurement group_id="O8" value="308.9" lower_limit="198.27" upper_limit="419.53"/>
                    <measurement group_id="O9" value="-17.8" lower_limit="-94.20" upper_limit="58.61"/>
                    <measurement group_id="O10" value="26.8" lower_limit="-30.03" upper_limit="83.70"/>
                    <measurement group_id="O11" value="122.5" lower_limit="69.82" upper_limit="175.26"/>
                    <measurement group_id="O12" value="248.0" lower_limit="137.72" upper_limit="358.33"/>
                    <measurement group_id="O13" value="-148.9" lower_limit="-269.62" upper_limit="-28.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Weight in the Overall Population and by Subgroups (Epoch 4)</title>
        <description>Between -treatment analysis of percentage change from Week 24 in body weight (kg) at Week 48 (Epoch 4)</description>
        <time_frame>Between Week 24 and Week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O2">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Weight in the Overall Population and by Subgroups (Epoch 4)</title>
          <description>Between -treatment analysis of percentage change from Week 24 in body weight (kg) at Week 48 (Epoch 4)</description>
          <population>Full Analysis Set</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.70" upper_limit="0.33"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.68" upper_limit="0.35"/>
                    <measurement group_id="O3" value="-2.4" lower_limit="-3.47" upper_limit="-1.33"/>
                    <measurement group_id="O4" value="0.4" lower_limit="-0.74" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.355</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.84</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.373</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.36</ci_lower_limit>
            <ci_upper_limit>-1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 (Epoch 3) in the 24-hour Urinary Calcium Excretion</title>
        <description>Evaluation of 24-hour urinary calcium excretion after 24 week of treatment.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 (Epoch 3) in the 24-hour Urinary Calcium Excretion</title>
          <description>Evaluation of 24-hour urinary calcium excretion after 24 week of treatment.</description>
          <population>Full Analysis Set</population>
          <units>mmol/24hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="20"/>
                    <count group_id="O9" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.6" spread="25.08"/>
                    <measurement group_id="O2" value="33.1" spread="29.65"/>
                    <measurement group_id="O3" value="40.2" spread="21.55"/>
                    <measurement group_id="O4" value="34.6" spread="17.56"/>
                    <measurement group_id="O5" value="44.7" spread="26.83"/>
                    <measurement group_id="O6" value="43.6" spread="16.91"/>
                    <measurement group_id="O7" value="38.0" spread="22.13"/>
                    <measurement group_id="O8" value="47.9" spread="23.64"/>
                    <measurement group_id="O9" value="43.0" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Timepoint 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" spread="26.59"/>
                    <measurement group_id="O2" value="38.1" spread="32.20"/>
                    <measurement group_id="O3" value="39.8" spread="22.48"/>
                    <measurement group_id="O4" value="40.1" spread="18.20"/>
                    <measurement group_id="O5" value="52.4" spread="32.78"/>
                    <measurement group_id="O6" value="45.9" spread="15.41"/>
                    <measurement group_id="O7" value="38.0" spread="22.13"/>
                    <measurement group_id="O8" value="48.1" spread="21.93"/>
                    <measurement group_id="O9" value="44.7" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Timepoint 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" spread="29.34"/>
                    <measurement group_id="O2" value="42.0" spread="29.99"/>
                    <measurement group_id="O3" value="39.2" spread="20.24"/>
                    <measurement group_id="O4" value="62.8" spread="34.26"/>
                    <measurement group_id="O5" value="51.2" spread="35.32"/>
                    <measurement group_id="O6" value="54.6" spread="23.77"/>
                    <measurement group_id="O7" value="37.9" spread="32.33"/>
                    <measurement group_id="O8" value="53.0" spread="26.95"/>
                    <measurement group_id="O9" value="52.2" spread="30.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Timepoint 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="38"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="22.74"/>
                    <measurement group_id="O2" value="3.9" spread="19.56"/>
                    <measurement group_id="O3" value="-0.6" spread="12.07"/>
                    <measurement group_id="O4" value="22.8" spread="28.42"/>
                    <measurement group_id="O5" value="-1.2" spread="7.77"/>
                    <measurement group_id="O6" value="8.7" spread="18.21"/>
                    <measurement group_id="O7" value="-0.1" spread="14.39"/>
                    <measurement group_id="O8" value="4.9" spread="26.20"/>
                    <measurement group_id="O9" value="7.5" spread="32.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Week 24 to Week 48 (Epoch 4) in the 24-hour Urinary Calcium Excretion</title>
        <description>Evaluation of 24-hour urinary calcium after 48 weeks of treatment</description>
        <time_frame>Baseline, Week 24, Week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O2">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Week 24 to Week 48 (Epoch 4) in the 24-hour Urinary Calcium Excretion</title>
          <description>Evaluation of 24-hour urinary calcium after 48 weeks of treatment</description>
          <population>Full Analysis Set</population>
          <units>mmol/24hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.02"/>
                    <measurement group_id="O2" value="5.0" spread="2.84"/>
                    <measurement group_id="O3" value="4.6" spread="0.91"/>
                    <measurement group_id="O4" value="5.6" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48(Timepoint 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="307"/>
                    <measurement group_id="O2" value="5.2" spread="2.95"/>
                    <measurement group_id="O3" value="4.5" spread="0.95"/>
                    <measurement group_id="O4" value="6.6" spread="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48(Timepoint 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="2.33"/>
                    <measurement group_id="O2" value="5.6" spread="4.55"/>
                    <measurement group_id="O3" value="5.4" spread="3.65"/>
                    <measurement group_id="O4" value="4.8" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48(Timepoint 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.41"/>
                    <measurement group_id="O2" value="0.4" spread="2.81"/>
                    <measurement group_id="O3" value="0.9" spread="4.10"/>
                    <measurement group_id="O4" value="-1.8" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 (Epoch 3) in the 24-hour Urinary Phosphorus Excretion</title>
        <description>Evaluation of 24-hour urinary phosphorus excretion after 24 weeks of treatment</description>
        <time_frame>Week 24, Week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 (Epoch 3) in the 24-hour Urinary Phosphorus Excretion</title>
          <description>Evaluation of 24-hour urinary phosphorus excretion after 24 weeks of treatment</description>
          <population>Full Analysis Set</population>
          <units>mmol/24hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="9"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="21"/>
                    <count group_id="O9" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282.1" spread="128.10"/>
                    <measurement group_id="O2" value="240.5" spread="74.64"/>
                    <measurement group_id="O3" value="254.5" spread="105.70"/>
                    <measurement group_id="O4" value="291.5" spread="175.10"/>
                    <measurement group_id="O5" value="284.0" spread="117.60"/>
                    <measurement group_id="O6" value="241.8" spread="82.75"/>
                    <measurement group_id="O7" value="277.0" spread="99.67"/>
                    <measurement group_id="O8" value="293.7" spread="120.70"/>
                    <measurement group_id="O9" value="297.0" spread="145.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Timepoint 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.0" spread="140.10"/>
                    <measurement group_id="O2" value="239.7" spread="80.40"/>
                    <measurement group_id="O3" value="260.9" spread="111.10"/>
                    <measurement group_id="O4" value="275.0" spread="101.30"/>
                    <measurement group_id="O5" value="319.9" spread="32.78"/>
                    <measurement group_id="O6" value="246.5" spread="84.19"/>
                    <measurement group_id="O7" value="299.3" spread="79.06"/>
                    <measurement group_id="O8" value="302.5" spread="121.30"/>
                    <measurement group_id="O9" value="307.9" spread="145.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Timepoint 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297.7" spread="117.40"/>
                    <measurement group_id="O2" value="295.3" spread="95.60"/>
                    <measurement group_id="O3" value="299.2" spread="145.50"/>
                    <measurement group_id="O4" value="264.7" spread="74.84"/>
                    <measurement group_id="O5" value="317.8" spread="205.10"/>
                    <measurement group_id="O6" value="341.6" spread="109.20"/>
                    <measurement group_id="O7" value="260.5" spread="124.80"/>
                    <measurement group_id="O8" value="289.3" spread="83.62"/>
                    <measurement group_id="O9" value="352.8" spread="159.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (Timepoint 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="132.00"/>
                    <measurement group_id="O2" value="55.6" spread="89.81"/>
                    <measurement group_id="O3" value="38.3" spread="70.00"/>
                    <measurement group_id="O4" value="-10.2" spread="103.60"/>
                    <measurement group_id="O5" value="-2.1" spread="159.60"/>
                    <measurement group_id="O6" value="95.1" spread="67.36"/>
                    <measurement group_id="O7" value="-38.7" spread="107.80"/>
                    <measurement group_id="O8" value="-13.2" spread="153.80"/>
                    <measurement group_id="O9" value="44.9" spread="177.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Week 24 to Week 48 (Epoch 4) in the 24-hour Urinary Phosphorus Excretion</title>
        <description>Evaluation of 24-hour urinary phosphorus excretion after 48 weeks of treatment</description>
        <time_frame>Week 24, Week 48</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O2">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Week 24 to Week 48 (Epoch 4) in the 24-hour Urinary Phosphorus Excretion</title>
          <description>Evaluation of 24-hour urinary phosphorus excretion after 48 weeks of treatment</description>
          <population>Full Analysis Set</population>
          <units>mmol/24hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="11.46"/>
                    <measurement group_id="O2" value="30.5" spread="11.63"/>
                    <measurement group_id="O3" value="28.6" spread="14.11"/>
                    <measurement group_id="O4" value="40.2" spread="15.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (Timepoint 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="11.73"/>
                    <measurement group_id="O2" value="30.2" spread="11.85"/>
                    <measurement group_id="O3" value="28.6" spread="14.11"/>
                    <measurement group_id="O4" value="44.4" spread="17.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (Timepoint 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" spread="12.74"/>
                    <measurement group_id="O2" value="31.1" spread="16.21"/>
                    <measurement group_id="O3" value="31.0" spread="14.67"/>
                    <measurement group_id="O4" value="29.0" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48(Timepoint 3)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="11.44"/>
                    <measurement group_id="O2" value="0.9" spread="14.52"/>
                    <measurement group_id="O3" value="2.4" spread="17.33"/>
                    <measurement group_id="O4" value="-15.5" spread="18.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Lipid Profile (Lipoproteins)</title>
        <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
        <time_frame>Baseline, Week 24, Week 24 to Week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
          <group group_id="O10">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O11">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O12">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O13">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Lipid Profile (Lipoproteins)</title>
          <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
          <population>Full Analysis Set</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="158"/>
                <count group_id="O11" value="163"/>
                <count group_id="O12" value="39"/>
                <count group_id="O13" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Apoliprotein A1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="71"/>
                    <count group_id="O9" value="78"/>
                    <count group_id="O10" value="151"/>
                    <count group_id="O11" value="152"/>
                    <count group_id="O12" value="36"/>
                    <count group_id="O13" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="4.26" upper_limit="13.61"/>
                    <measurement group_id="O2" value="8.13" lower_limit="3.27" upper_limit="13.30"/>
                    <measurement group_id="O3" value="10.7" lower_limit="5.38" upper_limit="15.97"/>
                    <measurement group_id="O4" value="8.9" lower_limit="5.55" upper_limit="12.21"/>
                    <measurement group_id="O5" value="5.3" lower_limit="0.487" upper_limit="10.17"/>
                    <measurement group_id="O6" value="8.1" lower_limit="3.44" upper_limit="12.86"/>
                    <measurement group_id="O7" value="6.7" lower_limit="1.75" upper_limit="11.59"/>
                    <measurement group_id="O8" value="11.0" lower_limit="7.47" upper_limit="14.44"/>
                    <measurement group_id="O9" value="6.7" lower_limit="3.41" upper_limit="10.06"/>
                    <measurement group_id="O10" value="3.0" lower_limit="0.92" upper_limit="5.10"/>
                    <measurement group_id="O11" value="3.4" lower_limit="1.22" upper_limit="5.51"/>
                    <measurement group_id="O12" value="5.6" lower_limit="1.35" upper_limit="9.89"/>
                    <measurement group_id="O13" value="-0.7" lower_limit="-5.27" upper_limit="3.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apoliprotein B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="75"/>
                    <count group_id="O9" value="78"/>
                    <count group_id="O10" value="151"/>
                    <count group_id="O11" value="152"/>
                    <count group_id="O12" value="36"/>
                    <count group_id="O13" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="-5.32" upper_limit="11.08"/>
                    <measurement group_id="O2" value="7.7" lower_limit="-1.23" upper_limit="16.61"/>
                    <measurement group_id="O3" value="3.3" lower_limit="-6.06" upper_limit="12.72"/>
                    <measurement group_id="O4" value="12.4" lower_limit="6.57" upper_limit="18.32"/>
                    <measurement group_id="O5" value="-0.4" lower_limit="-8.91" upper_limit="8.18"/>
                    <measurement group_id="O6" value="4.5" lower_limit="-3.84" upper_limit="12.74"/>
                    <measurement group_id="O7" value="2.3" lower_limit="-6.36" upper_limit="10.98"/>
                    <measurement group_id="O8" value="3.9" lower_limit="-2.29" upper_limit="10.01"/>
                    <measurement group_id="O9" value="5.8" lower_limit="-0.03" upper_limit="11.69"/>
                    <measurement group_id="O10" value="-1.7" lower_limit="-4.39" upper_limit="1.08"/>
                    <measurement group_id="O11" value="-2.4" lower_limit="-5.23" upper_limit="0.38"/>
                    <measurement group_id="O12" value="-2.3" lower_limit="-7.85" upper_limit="3.31"/>
                    <measurement group_id="O13" value="-2.0" lower_limit="-8.00" upper_limit="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitive C-reactive Protein (hsCRP)</title>
        <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
        <time_frame>Baseline to Week 24, Week 24 to Week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
          <group group_id="O10">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O11">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O12">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O13">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitive C-reactive Protein (hsCRP)</title>
          <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
          <population>Full Analysis Set</population>
          <units>mg/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="158"/>
                <count group_id="O11" value="163"/>
                <count group_id="O12" value="39"/>
                <count group_id="O13" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" lower_limit="0.78" upper_limit="1.25"/>
                    <measurement group_id="O2" value="1.06" lower_limit="0.83" upper_limit="1.36"/>
                    <measurement group_id="O3" value="1.31" lower_limit="1.01" upper_limit="1.69"/>
                    <measurement group_id="O4" value="0.98" lower_limit="0.83" upper_limit="1.16"/>
                    <measurement group_id="O5" value="1.02" lower_limit="0.80" upper_limit="1.30"/>
                    <measurement group_id="O6" value="0.93" lower_limit="0.74" upper_limit="118"/>
                    <measurement group_id="O7" value="1.00" lower_limit="0.78" upper_limit="1.27"/>
                    <measurement group_id="O8" value="0.98" lower_limit="0.83" upper_limit="1.17"/>
                    <measurement group_id="O9" value="0.92" lower_limit="0.78" upper_limit="1.09"/>
                    <measurement group_id="O10" value="0.95" lower_limit="0.85" upper_limit="1.06"/>
                    <measurement group_id="O11" value="0.93" lower_limit="0.83" upper_limit="1.04"/>
                    <measurement group_id="O12" value="0.96" lower_limit="0.77" upper_limit="1.20"/>
                    <measurement group_id="O13" value="1.07" lower_limit="0.84" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.632</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.352</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.027</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.587</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.508</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.945</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.602</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.612</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.382</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.310</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.525</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Lipid Profile (Triglycerides/Cholesterol)</title>
        <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
        <time_frame>Baseline to Week 24, Week 24 to Week 48 (Epoch 4)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O9">
            <title>Placebo (Epoch 3)</title>
            <description>Matching placebo tablets for 24 weeks</description>
          </group>
          <group group_id="O10">
            <title>LIK066 qd/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O11">
            <title>LIK066 Bid/LIK066 35mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O12">
            <title>Placebo/LIK066 25mg qd (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
          <group group_id="O13">
            <title>Placebo/Placebo (Epoch 4)</title>
            <description>Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Lipid Profile (Triglycerides/Cholesterol)</title>
          <description>Between-treatment analysis of change after 24 weeks of treatment and between Week 24 and Week 48</description>
          <population>Full Analysis Set</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="76"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="158"/>
                <count group_id="O11" value="163"/>
                <count group_id="O12" value="39"/>
                <count group_id="O13" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triglycerides (TG)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="38"/>
                    <count group_id="O8" value="71"/>
                    <count group_id="O9" value="78"/>
                    <count group_id="O10" value="150"/>
                    <count group_id="O11" value="149"/>
                    <count group_id="O12" value="36"/>
                    <count group_id="O13" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" lower_limit="-14.91" upper_limit="7.26"/>
                    <measurement group_id="O2" value="1.3" lower_limit="-11.19" upper_limit="13.80"/>
                    <measurement group_id="O3" value="-11.5" lower_limit="-24.03" upper_limit=".093"/>
                    <measurement group_id="O4" value="-3.0" lower_limit="-10.94" upper_limit="4.91"/>
                    <measurement group_id="O5" value="2.3" lower_limit="-8.94" upper_limit="13.57"/>
                    <measurement group_id="O6" value="1.7" lower_limit="-9.30" upper_limit="12.77"/>
                    <measurement group_id="O7" value="5.5" lower_limit="-5.94" upper_limit="16.89"/>
                    <measurement group_id="O8" value="-7.4" lower_limit="-15.60" upper_limit="0.87"/>
                    <measurement group_id="O9" value="4.0" lower_limit="-3.82" upper_limit="11.87"/>
                    <measurement group_id="O10" value="6.7" lower_limit="0.18" upper_limit="13.13"/>
                    <measurement group_id="O11" value="12.4" lower_limit="5.75" upper_limit="19.13"/>
                    <measurement group_id="O12" value="-0.9" lower_limit="-14.48" upper_limit="12.59"/>
                    <measurement group_id="O13" value="4.8" lower_limit="-9.57" upper_limit="19.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol (TC)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="71"/>
                    <count group_id="O9" value="78"/>
                    <count group_id="O10" value="151"/>
                    <count group_id="O11" value="152"/>
                    <count group_id="O12" value="36"/>
                    <count group_id="O13" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="-0.92" upper_limit="12.99"/>
                    <measurement group_id="O2" value="7.3" lower_limit="-0.23" upper_limit="14.92"/>
                    <measurement group_id="O3" value="4.8" lower_limit="-3.15" upper_limit="12.78"/>
                    <measurement group_id="O4" value="14.6" lower_limit="9.61" upper_limit="19.58"/>
                    <measurement group_id="O5" value="1.5" lower_limit="-5.79" upper_limit="8.71"/>
                    <measurement group_id="O6" value="5.1" lower_limit="-1.89" upper_limit="12.19"/>
                    <measurement group_id="O7" value="6.4" lower_limit="-0.94" upper_limit="13.75"/>
                    <measurement group_id="O8" value="8.8" lower_limit="-0.23" upper_limit="9.70"/>
                    <measurement group_id="O9" value="4.7" lower_limit="-0.23" upper_limit="9.70"/>
                    <measurement group_id="O10" value="0.8" lower_limit="-1.65" upper_limit="3.27"/>
                    <measurement group_id="O11" value="0.3" lower_limit="-2.22" upper_limit="2.81"/>
                    <measurement group_id="O12" value="0.8" lower_limit="-4.22" upper_limit="5.81"/>
                    <measurement group_id="O13" value="-1.7" lower_limit="-7.04" upper_limit="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="71"/>
                    <count group_id="O9" value="78"/>
                    <count group_id="O10" value="151"/>
                    <count group_id="O11" value="152"/>
                    <count group_id="O12" value="36"/>
                    <count group_id="O13" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-5.25" upper_limit="6.76"/>
                    <measurement group_id="O2" value="4.9" lower_limit="-1.52" upper_limit="11.28"/>
                    <measurement group_id="O3" value="5.2" lower_limit="-1.55" upper_limit="12.01"/>
                    <measurement group_id="O4" value="8.0" lower_limit="3.71" upper_limit="12.25"/>
                    <measurement group_id="O5" value="2.9" lower_limit="-3.29" upper_limit="9.16"/>
                    <measurement group_id="O6" value="2.4" lower_limit="-3.60" upper_limit="8.48"/>
                    <measurement group_id="O7" value="1.5" lower_limit="-4.86" upper_limit="7.81"/>
                    <measurement group_id="O8" value="8.0" lower_limit="3.56" upper_limit="12.47"/>
                    <measurement group_id="O9" value="0.7" lower_limit="-3.54" upper_limit="5.00"/>
                    <measurement group_id="O10" value="3.9" lower_limit="0.84" upper_limit="7.03"/>
                    <measurement group_id="O11" value="3.7" lower_limit="0.54" upper_limit="6.90"/>
                    <measurement group_id="O12" value="9.2" lower_limit="2.88" upper_limit="15.57"/>
                    <measurement group_id="O13" value="0.7" lower_limit="-6.11" upper_limit="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="71"/>
                    <count group_id="O9" value="78"/>
                    <count group_id="O10" value="151"/>
                    <count group_id="O11" value="152"/>
                    <count group_id="O12" value="36"/>
                    <count group_id="O13" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="-2.14" upper_limit="19.61"/>
                    <measurement group_id="O2" value="17.5" lower_limit="5.73" upper_limit="29.20"/>
                    <measurement group_id="O3" value="8.2" lower_limit="-4.21" upper_limit="20.25"/>
                    <measurement group_id="O4" value="21.8" lower_limit="14.08" upper_limit="29.55"/>
                    <measurement group_id="O5" value="4.1" lower_limit="-7.22" upper_limit="15.38"/>
                    <measurement group_id="O6" value="8.7" lower_limit="-2.26" upper_limit="19.68"/>
                    <measurement group_id="O7" value="7.7" lower_limit="-3.77" upper_limit="19.13"/>
                    <measurement group_id="O8" value="10.9" lower_limit="2.80" upper_limit="19.04"/>
                    <measurement group_id="O9" value="12.5" lower_limit="4.70" upper_limit="20.30"/>
                    <measurement group_id="O10" value="-0.6" lower_limit="-4.14" upper_limit="2.96"/>
                    <measurement group_id="O11" value="-1.2" lower_limit="-4.79" upper_limit="2.49"/>
                    <measurement group_id="O12" value="-1.4" lower_limit="-8.66" upper_limit="5.83"/>
                    <measurement group_id="O13" value="-3.5" lower_limit="-11.28" upper_limit="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.254</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.37</ci_lower_limit>
            <ci_upper_limit>5.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.716</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.44</ci_lower_limit>
            <ci_upper_limit>11.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.038</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-15.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.30</ci_lower_limit>
            <ci_upper_limit>-0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.213</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-7.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.15</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.806</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.38</ci_lower_limit>
            <ci_upper_limit>11.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.739</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.80</ci_lower_limit>
            <ci_upper_limit>11.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.837</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.36</ci_lower_limit>
            <ci_upper_limit>15.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.71</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.764</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.22</ci_lower_limit>
            <ci_upper_limit>9.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.571</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.43</ci_lower_limit>
            <ci_upper_limit>11.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.987</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.30</ci_lower_limit>
            <ci_upper_limit>9.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.85</ci_lower_limit>
            <ci_upper_limit>16.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.463</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.03</ci_lower_limit>
            <ci_upper_limit>5.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.925</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.18</ci_lower_limit>
            <ci_upper_limit>9.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.711</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.19</ci_lower_limit>
            <ci_upper_limit>10.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.265</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.10</ci_lower_limit>
            <ci_upper_limit>11.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.995</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.31</ci_lower_limit>
            <ci_upper_limit>7.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.288</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.52</ci_lower_limit>
            <ci_upper_limit>11.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.269</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.50</ci_lower_limit>
            <ci_upper_limit>12.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>13.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.565</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.32</ci_lower_limit>
            <ci_upper_limit>9.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.649</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.67</ci_lower_limit>
            <ci_upper_limit>9.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.847</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.87</ci_lower_limit>
            <ci_upper_limit>8.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>13.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.579</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.09</ci_lower_limit>
            <ci_upper_limit>9.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.487</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.08</ci_lower_limit>
            <ci_upper_limit>19.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.561</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.96</ci_lower_limit>
            <ci_upper_limit>10.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>9.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.68</ci_lower_limit>
            <ci_upper_limit>20.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.227</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.10</ci_lower_limit>
            <ci_upper_limit>5.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.580</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.22</ci_lower_limit>
            <ci_upper_limit>9.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.494</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.67</ci_lower_limit>
            <ci_upper_limit>9.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.782</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.81</ci_lower_limit>
            <ci_upper_limit>9.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.816</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.82</ci_lower_limit>
            <ci_upper_limit>17.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.341</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.13</ci_lower_limit>
            <ci_upper_limit>23.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Triglycerides (TG)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.566</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>9.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.39</ci_lower_limit>
            <ci_upper_limit>13.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.405</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.38</ci_lower_limit>
            <ci_upper_limit>8.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.511</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.92</ci_lower_limit>
            <ci_upper_limit>7.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Total Cholesterol (TC)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.506</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.83</ci_lower_limit>
            <ci_upper_limit>9.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.392</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.20</ci_lower_limit>
            <ci_upper_limit>10.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.426</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.45</ci_lower_limit>
            <ci_upper_limit>10.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>HDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.071</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>17.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.498</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.56</ci_lower_limit>
            <ci_upper_limit>11.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.586</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.17</ci_lower_limit>
            <ci_upper_limit>10.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>LDL Cholesterol</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Dose finding study</non_inferiority_desc>
            <p_value>0.696</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.47</ci_lower_limit>
            <ci_upper_limit>12.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of LIK066: Observe Maximum Plasma Concentration (Cmax)</title>
        <description>Observe maximum plasma concentration following administration of LIK066 (Cmax)</description>
        <time_frame>Summary at Week 24 from qd or bid regimens</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of LIK066: Observe Maximum Plasma Concentration (Cmax)</title>
          <description>Observe maximum plasma concentration following administration of LIK066 (Cmax)</description>
          <population>Full Analysis Set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" spread="97.2"/>
                    <measurement group_id="O2" value="128" spread="00.0"/>
                    <measurement group_id="O3" value="798" spread="397"/>
                    <measurement group_id="O4" value="1810" spread="545"/>
                    <measurement group_id="O5" value="38.6" spread="5.22"/>
                    <measurement group_id="O6" value="84.2" spread="19.0"/>
                    <measurement group_id="O7" value="523" spread="118"/>
                    <measurement group_id="O8" value="811" spread="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of LIK066: Time to Reach the Maximum Concentration (Tmax)</title>
        <description>Time to reach the maximum concentration after administration of LIK066 (Tmax)</description>
        <time_frame>Summary at Week 24 for qd or bid regimens</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of LIK066: Time to Reach the Maximum Concentration (Tmax)</title>
          <description>Time to reach the maximum concentration after administration of LIK066 (Tmax)</description>
          <population>Full Analysis Set</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="1.00"/>
                    <measurement group_id="O3" value="1.01" lower_limit="1.00" upper_limit="2.08"/>
                    <measurement group_id="O4" value="1.02" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.983" upper_limit="1.00"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.917" upper_limit="2.00"/>
                    <measurement group_id="O7" value="0.992" lower_limit="0.900" upper_limit="1.00"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.983" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of LIK066: Area Under the Plasma Concentration-time Curve From Time Zero Time 't' (AUC0-t)</title>
        <description>Area under the plasma concentration-time curve from time zero time 't' where t is a defined time point after administration (AUC0-t)</description>
        <time_frame>Summary at Week 24 from qd or bid regimens (0-6h)</time_frame>
        <population>Full Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of LIK066: Area Under the Plasma Concentration-time Curve From Time Zero Time 't' (AUC0-t)</title>
          <description>Area under the plasma concentration-time curve from time zero time 't' where t is a defined time point after administration (AUC0-t)</description>
          <population>Full Analysis Population</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" spread="186"/>
                    <measurement group_id="O2" value="275" spread="000"/>
                    <measurement group_id="O3" value="2280" spread="522"/>
                    <measurement group_id="O4" value="5700" spread="1490"/>
                    <measurement group_id="O5" value="105" spread="17.1"/>
                    <measurement group_id="O6" value="273" spread="69.3"/>
                    <measurement group_id="O7" value="1520" spread="277"/>
                    <measurement group_id="O8" value="2190" spread="841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of LIK066: Last Non-zero Concentration Area Under the Curve (AUClast)</title>
        <description>Last non-zero concentration area under the curve (AUClast)</description>
        <time_frame>Summary at Week 24 from qd or bid regimens</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>LIK066 2.5mg qd (Epoch 3)</title>
            <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>LIK066 10mg qd (Epoch 3)</title>
            <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>LIK066 50mg qd (Epoch 3)</title>
            <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>LIK066 150mg qd (Epoch 3)</title>
            <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O5">
            <title>LIK066 2.5mg Bid (Epoch 3)</title>
            <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O6">
            <title>LIK066 5mg Bid (Epoch 3)</title>
            <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O7">
            <title>LIK066 25mg Bid (Epoch 3)</title>
            <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
          <group group_id="O8">
            <title>LIK066 50mg Bid (Epoch 3)</title>
            <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of LIK066: Last Non-zero Concentration Area Under the Curve (AUClast)</title>
          <description>Last non-zero concentration area under the curve (AUClast)</description>
          <population>Full Analysis Set</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196" spread="186"/>
                    <measurement group_id="O2" value="275" spread="000"/>
                    <measurement group_id="O3" value="2290" spread="526"/>
                    <measurement group_id="O4" value="5690" spread="1480"/>
                    <measurement group_id="O5" value="105" spread="17.2"/>
                    <measurement group_id="O6" value="273" spread="70.2"/>
                    <measurement group_id="O7" value="1520" spread="271"/>
                    <measurement group_id="O8" value="2190" spread="843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment, plus 30 days post treatment, up to maximum duration of approximately 15 months.</time_frame>
      <desc>Any sign or symptom that occurs during the study treatment plus the 30 days post treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>LIK066 2.5 mg qd (Epoch 3)/25 mg qd (Epoch 4)</title>
          <description>LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks (Epoch3), then LIK066 25 mg qd for 24 weeks (Epoch 4)</description>
        </group>
        <group group_id="E2">
          <title>LIK066 10 mg qd/25 mg qd</title>
          <description>LIK066 10mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>LIK066 50 mg qd/25 mg qd</title>
          <description>LIK066 50mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="E4">
          <title>LIK066 150 mg qd/25 mg qd</title>
          <description>LIK066 150mg qd (once daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="E5">
          <title>LIK066 2.5 mg Bid/35 mg qd</title>
          <description>LIK066 2.5mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="E6">
          <title>LIK066 5 mg Bid/35 mg qd</title>
          <description>LIK066 5mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="E7">
          <title>LIK066 25 mg Bid/35 mg qd</title>
          <description>LIK066 25mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="E8">
          <title>LIK066 50 mg Bid/35 mg qd</title>
          <description>LIK066 50mg bid (twice daily) dosing frequency for 24 weeks</description>
        </group>
        <group group_id="E9">
          <title>Placebo/LIK066 25 mg qd (Epoch 4)</title>
          <description>Matching placebo tablets for 24 weeks</description>
        </group>
        <group group_id="E10">
          <title>Placebo/Placebo</title>
          <description>Matching placebo tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="47" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="32" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="32" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Porokeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Type IIa hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eustachian tube dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eye movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myopic chorioretinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyschezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eosinophilic oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Faeces hard</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Splenic artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bacterial vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cystitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Genital herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Otitis externa fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Apolipoprotein A-I decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood albumin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Creatinine urine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Electrocardiogram change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Haematocrit increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Haemoglobin urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lipase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Liver scan abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Serum ferritin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Extremity contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of conjunctiva</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyposmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Unintended pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Binge drinking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Grief reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Organic brain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lower urinary tract symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

